EnGeneIC, ADRI begin MesomiR-1 Phase I trial in patients with late stage Mesothelioma
The study is the first time a targeted nanotherapeutic approach to microRNA replacement is being tested in patients with MPM. EnGeneIC’s EDV nanocells will be packaged with miR-16
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.